Prevalence of latent tuberculosis in patients with hematological neoplasms in a cancer referral hospital in Mexico City

Abstract

Objective To determine the prevalence of Latent Tuberculosis in patients with hematological neoplasms at the Instituto Nacional de Cancerología in Mexico City using the Tuberculin skin test (TST). Methods This retrospective study included all patients with a recent diagnosis of hematological neoplasms who were admitted for treatment from 2017 to 2018 and who were screened for latent tuberculosis with the TST. The prevalence of latent tuberculosis in this group, tolerance and therapeutic adherence in treated patients are described. Results The files of 446 patients with hematological malignancy who had a TST were reviewed. The prevalence of latent tuberculosis was 31.2% (n = 139). Ninety-three patients received isoniazid, 15.1% had some adverse reactions, but only 4 (4.3%) had to discontinue treatment. Two patients with latent tuberculosis under treatment with Isoniazid reactivated tuberculosis infection. Conclusions The prevalence in our study was within the range of other similar Mexican populations. Isoniazid treatment had an adequate tolerance and adherence. Longer follow-up could offer more information on the risk of reactivation in both groups.

Tuberculin skin test versus QuantiFERON-TB gold in-tube for latent tuberculosis screening in people living with HIV in a resource-limited setting

“…23 Outside the border region, the prevalence of LTBI in Mexico has been less studied, but still shows higher rates. 24,25 In the absence of a gold standard, it had been described that using both QFT and TST would increase the detection of LTBI in PLWHIV compared with TST alone; 26,27 our study showed an increase from 6.8% to 11.2%, similar to the findings of Kussen et al, 26 who reported an increase from 9% to 17%.…”

“…2 To our knowledge, this is the largest cohort published in Mexican PLWHIV evaluating a real-life situation to improve LTBI detection. We found an LTBI prevalence of 11.2%, which is lower than the one reported in other cities in our country (31–57%); 5,23,24 this can be attributed to high-risk characteristics of their studied populations, such as a high proportion of injection drug users and female sex workers in Tijuana (U.S. border city) 5 or the migratory process from Latin America, that takes place in the US-Mexico border states; this region accounts for 30% of total reported TB cases among both countries. 23 Outside the border region, the prevalence of LTBI in Mexico has been less studied, but still shows higher rates.…”

“…23 Outside the border region, the prevalence of LTBI in Mexico has been less studied, but still shows higher rates. 24,25…”

Implementation of a Routine Screening Program for Latent Tuberculosis Infection among Patients with Acute Leukemia at a Canadian Cancer Center

“…However, our cohort was considerably larger and was more homogenous as it involved only patients with acute leukemia. In contrast, Orsorio-Lopez and colleagues demonstrated a higher prevalence of 31.2% for LTBI infections when focusing primarily on non-Hodgkin’s and Hodgkin’s lymphoma patients who comprised 347 of 446 (77.8%) of the patients with hematologic malignancies [ 17 ]. They considered a positive TST to be 5 mm of induration and observed that 250 out of 446 (56.1%) patients were vaccinated for BCG [ 17 ].…”

Management of Latent Tuberculosis Infection Based on T-SPOT.TB Assay in Patients With Hematological Malignancies

“… 11 Elevated liver enzymes caused by INH therapy have been determined in various ways in the literature. Osorio-López et al 12 planned INH as LTBI treatment for 93 patients with HM for nine months, and they observed 15.1% of drug-related adverse effects. 4.3% of the patients had to discontinue the treatment due to side effects related to INH, and 3.2% (n=3) of them were due to elevated liver enzymes.…”